Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.46 |
| ▸ | GABRP | O00591 | 10/20 | 0.44 |
| ▸ | GABRD | O14764 | 10/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 10/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 10/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 10/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 10/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 10/20 | 0.44 |
| ▸ | GABRE | P78334 | 10/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 10/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 10/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 10/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15921034 | 0.84 | ALDH1A1 (0.52) | LMNAALDH1A1TSHRMAPK1LIMK1 | |
| SCHEMBL10227767 | 0.81 | ALDH1A1 (0.59) | LMNAALDH1A1TSHRMAPK1LIMK1 | |
| SCHEMBL15921481 | 0.75 | LIMK1 (0.51) | LMNAALDH1A1LIMK1HTTHSD17B10 | |
| SCHEMBL2084756 | 0.75 | EGFR (0.68) | MAPK1HTT | |
| SCHEMBL2085627 | 0.74 | HTT (0.58) | LMNAALDH1A1TSHRMAPK1GABRP | |
| SCHEMBL15921132 | 0.73 | LIMK1 (0.49) | LMNAALDH1A1LIMK1HTTHSD17B10 | |
| SCHEMBL15921053 | 0.73 | LIMK1 (0.49) | LMNAALDH1A1LIMK1HTTHSD17B10 | |
| SCHEMBL6315989 | 0.73 | LIMK1 (0.69) | LMNAALDH1A1TSHRMAPK1LIMK1 | |
| SCHEMBL15921184 | 0.73 | GABRP (0.41) | LMNAALDH1A1TSHRMAPK1LIMK1 | |
| SCHEMBL15534077 | 0.73 | LIMK1 (0.45) | LMNAALDH1A1LIMK1P2RX3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159816-A1 | SUBSTITUTED THIENOPYRIMIDINES AND PHARMACEUTICAL USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159816-A1 | SUBSTITUTED THIENOPYRIMIDINES AND PHARMACEUTICAL USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-2951187-A1 | SUBSTITUTED THIENOPYRIMIDINES AND PHARMACEUTICAL USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014118229-A1 | SUBSTITUTED THIENOPYRIMIDINES AND PHARMACEUTICAL USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014118229-A1 | SUBSTITUTED THIENOPYRIMIDINES AND PHARMACEUTICAL USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-07 | — | — | WO | disclosed |
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1799653-A2 | NOVEL HETEROCYCLES | Bayer Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1651652-B1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1651652-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006044524-A1 | BENZOTHIENO’2,3-D! PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006023843-A2 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005010008-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159816-A1 | SUBSTITUTED THIENOPYRIMIDINES AND PHARMACEUTICAL USE THEREOF | TYMP, DPYD, TYMS | LMNA 4202/4885ALDH1A1 507/4885TSHR 3295/4885 |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | MKI67, PCNA, MYC | LMNA 3440/4885ALDH1A1 414/4885TSHR 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.